ISFA 2025 SCIENTIFIC PROGRAM

| Time | Mayfair A-B | Mayfair C | Jubilee | | |
|---------------|---|---|--|--|--|
| | | Thursday, July 17 | | | |
| 07:00 - 08:00 | 0 Registration | | | | |
| 08:00 - 09:30 | Apheresis around the world 1: joint workshop with JSFA | Apheresis in sepsis and ARDS: mechanisms, therapies, and clinical applications | | | |
| | Chair: Ken Yamaji (Japan) | Chair: Tadao Akizawa (Japan) | | | |
| | Chair: Kriengsak Vareesangthip (Thailand) | Chair: Dusit Lumlertgul (Thailand) | | | |
| | Keynote address "Current status of therapeutic apheresis in Japan 1" (5 min) | Apheresis treatment in critical care setting (25+5 min) | | | |
| | Ken Yamaji (Japan) | Jan Kielstein (Germany) | | | |
| | Efficacy of plasma exchange for rapidly progressive interstitial lung disease (RP-ILD) in anti-MDA5-positive dermatomyositis (DM) (20+7 min) | Extracorporeal blood purification for sepsis; emerging role of apheresis? (25+5 min) | | | |
| | Makio Kusaoi (Japan) | Rasheed Abiodun Balogun (USA) | | | |
| | Granulocyte monocyte apheresis (GMA) for ulcerative colitis (UC) (20+7 min) | Extracorporeal blood purification for sepsis: role of adsorptive therapy (25+5 min) | | | |
| | Yoko Yokoyama (Japan) | Ranistha Ratanarat (Thailand) | | | |
| | Evolving treatment strategies for patients with chronic limb-threatening ischemia in Japan-viscosity intervention with Rheocarna therapy after revascularization (20+7 min) | | | | |
| | Keisuke Miyake (Japan) | | | | |
| 09:30 - 10:30 | | Opening ceremony and plenary lecture | | | |
| | Current status and future challenges for apheresis in Thailand | | | | |
| | | Chair: Ken Yamaji (Japan) | | | |
| | | Speaker: Kriengsak Vareesangthip (Thailand) | | | |
| 10:30 - 11:00 | | Coffee Break and Poster Visiting | | | |
| 11:00 - 12:30 | Apheresis around the world 2: | Extracorporeal therapies in liver failure and critical illness: innovations in CRRT, plasma | Apheresis onboarding: nursing and advanced | | |
| | joint workshop with JSFA | exchange, and adsorptive techniques | practice providers | | |
| | Chair: Ken Yamaji (Japan) | Chair: Wladimir Szpirt (Denmark) | Chair: Wanphen Plakmueang (Thailand) | | |
| | Chair: Suchai Sritippayawan (Thailand) | Chair: Nattachai Srisawat (Thailand) | Principle of apheresis method: principle of membrane and centrifugal plasmapheresis | | |
| | Keynote address "Current status of therapeutic apheresis in Japan 2" (5 min) | Role of CRRT in liver failure (15+5 min) | Suchada Boonkaew (Thailand) | | |
| | Ken Yamaji (Japan) | Thummaporn Naorungroj (Thailand) | Nursing management for therapeutic apheresis (pre-during-post) | | |
| | Apheresis therapy in secondary nephritic syndrome and/or diabetic kidney disease (20+7 min) | Total plasma exchange: a therapeutic approach (15+5 min) | Patcharin Injan (Thailand) | | |
| | Kengo Furuichi (Japan) | Phitphiboon Deawtrakulchai (Thailand) | | | |
| | Apheresis therapy in the treatment strategy of neuromyelitis optica spectrum disorder (NMOSD) (20+7 min) | Adsorptive therapies: innovations and applications (15+5 min) | | | |
| | Youwei Lin (Japan) | Nuttha Lumlertgul (Thailand) | | | |
| | Therapeutic apheresis for respiratory infections associated with COVID-19 infection (20+7 min) | Abstract O-017 | | | |
| | Daisuke Katagiri (Japan) | Galectin-3 apheresis - a promising therapy for Sepsis and Sepsis Associated Acute Kidney Injury (SA-AKI) | | | |
| | | Isaac Eliaz, Zhongyi Sun, Peng Zhiyong | | | |
| | | Abstract O-008 | | | |
| | | LPS hemoadsorption in the treatment of patients with obstetric sepsis | | | |

| | | Gurbanova Samira, Fedorova Tatiana, Rogachevskiy Oleg, Strelnikova Elena, Trposhin | |
|---------------|--|--|--|
| | | Pavel, Piregov Aleksey, Khamidulina Ksenia, Vereshchagin Alexey, Belotserkovtseva | |
| | | Larisa | |
| 12:30 - 13:30 | | Lunch Symposium | Lunch Symposium |
| | Fresinius Kabi | Lipoprotein apheresis in cardiovascular disease: evolving strategies in FH and | |
| | | peripheral arterial disease | |
| | | Chair: Luigi Vernaglione (Italy) | |
| | | Chair: Adisorn Lumpaopong (Thailand) | |
| | | The current status of lipoprotein apheresis in familial hypercholesterolemia (FH) | |
| | | treatment with the use of molecular targeted drugs (25+5 min) | |
| | | Mariko Harada-Shiba | |
| | | Apheresis with lipid and fibrinogen in peripheral arterial disease (25+5 min) | |
| | | Dusit Lumlertgul (Thailand) | |
| 13:30 - 15:00 | Apheresis around the world 3: | Evolving role of apheresis in autoimmune kidney diseases | Apheresis onboarding: nursing and advanced |
| | joint workshop with E-ISFA "Lipidology" | | practice providers |
| | Chair: Bernd Hohenstein (Germany) | Chair: Makio Kusaoi (Japan) | Chair: Wanphen Plakmueang (Thailand) |
| | Chair: Dusit Lumlertgul (Thailand) | Chair: Kolasorn Pakchotanon (Thailand) | |
| | Is lipoprotein apheresis effective for coronary microvascular dysfunction in CHD | Apheresis in action: breaking barriers in autoimmune kidney disease treatment (17+5 | |
| | patients? (25+5 min) | min) | Vascular access in therapeutic apheresis: Nurse Role |
| | Alfonso Ramunni (Italy) | , Wanjak Pongsittisak (Thailand) | Saowaros Parinyachitta (Thailand) |
| | Apheresis treatment to improve rheology and microcirculation – indications and results | | Nursing management for complication and adverse |
| | (25+5 min) | · · · · · · · · · · · · · · · · · · · | event therapeutic apheresis |
| | Luigi Vernaglione (Italy) | Ratana Chawanasuntorapoj (Thailand) | Rudchanu Baosingsua |
| | | Antinephrin-associated primary FSGS successfully treated with plasmapheresis - A case | |
| | (25+5 min) | report (17+5 min) | |
| | Wolfgang Ramlow (Germany) | lain Bressendorff, Karl Emil Nelveg-Kristensen, Maryam Ghasemi, Andrew J.B. Watts, | |
| | wongung runnow (ochnuny) | Johanna Elversang, Keith H. Keller, Finn Cilius Nielsen, <u>Wladimir Szpirt</u> , Astrid Weins | |
| | | | |
| | | Abstract O-011 | |
| | | Efficacy and Safety of Centrifugal Plasmapheresis in Nephrology: A Multicenter Study | |
| | | Across North India | |
| | | Divya Setya, Divya Setya, Ankit Malhotra, Shahwan Akhtar, Arghyadeep Marik, Ramesh | |
| | | Yadav | |
| 15:00 - 15:30 | | Coffee Break and Poster Visiting | |
| 15:30 - 17:00 | | | Apheresis onboarding: nursing and advanced |
| 15.50 - 17.00 | joint workshop with E-ISFA "Autoimmunity" | Role of lipoprotein apheresis in managing severe lipid disorders and cardiovascular diseases | practice providers |
| | | | · · · · · · · · · · · · · · · · · · · |
| | | | Chair: Wanphen Plakmueang (Thailand) |
| | | Chair: Pongsathorn Gojaseni (Thailand) | De distrie ale sus ale sus size a une a sele |
| | Immunoadsorption – techniques and indications from a European perspective (25+5 | Apheresis in patients with homozygous familial hypercholesterolemia (HoFH) – Indian | Pediatric plasmapheresis: nurse role |
| | min) | experience (25+5 min) | |
| | Bernd Hohenstein (Germany) | Shamanna S. Iyengar (India) | Salee Jaiprong (Thailand) |
| | Immunoadsorption in steroid-refractory multiple sclerosis (MS) (25+5 min) | Lipoprotein apheresis: utility, outcomes and implementation in clinical practice from a | |
| | | US perspective (25+5 min) | |
| | Johannes Dorst (Germany) | Paul Barton Duell (USA) | |
| | The role of immunoadsorption in chronic inflammatory demyelinating polyneuropathy | Abstract O-016 | |
| | (CIDP) (25+5 min) | | |
| | Zeynep Elmas (Germany) | Effective utilization of lipoprotein apheresis in a patient with elevated serum levels of | |
| | | LDL cholesterol: A case series from the Heart Center in Kazakhstan | |
| | | | |
| | | Mahabbat Bekbossynova, Bolat Bekishev, Tatyana Ivanova-Razumova, Dariga | |
| | | Koichubayeva, Ainamkoz Amanzholova | |

| | | Abstract O-025 | |
|---------------|--|--|---|
| | | Apoprotein B is a useful biomarker for apheresis with the Rheocarna in patients with | |
| | | no-option chronic limb-threatening ischemia | |
| | | Hitoshi Suzuki | |
| Time | Room 1 | Room 2 | Jubilee |
| | | Friday, Juuly 18 | |
| 07:30 - 08:30 | Morning Symposium | Morning Symposium | |
| | Terumo BCT: Similar but not the same – Dawn of a new age for Centrifugal Therapeutic | JIMRO: Apheresis treatment for reshaping immunological balance in Inflammatory | |
| | Plasma Exchange (cTPE) | Bowel Disease (IBD) | |
| | Opening remarks & Meeting objectives | Chair: Wolfgang Ramlow (Germany) | |
| | Metha Apiwattanakul (Thailand) | Speaker: Yoko Yokoyama (Japan) | |
| | A change for better exchange: Dawn of cTPE | | |
| | Mickael Beraud (France) | | |
| | The efficacy of centrifugal plasma exchange and our vision for outpatient apheresis | | |
| | therapy | | |
| | Daisuke Katagiri (Japan) | | |
| 08:30 - 10:00 | Key aspects of apheresis in nephrology, metabolic effects, national practice trends, and | Advancing therapeutic apheresis: perspectives, challenges, and innovations | Apheresis onboarding: nursing and advanced |
| | sustainability | | practice providers |
| | Chair: Jan Kielstein (Germany) | Chair: Nicole A. Aqui (USA) | Chair: Narunat Keereewan (Thailand) |
| | Chair: Arkom Nongnuch (Thailand) | Chair: Parichart Permpikul (Thailand) | Nursing management for CRRT combined with |
| | | | plasmapheresis |
| | It's not the citrate! Impact of plasma exchange on calcium, phosphorus, vitamin D and parathyroid hormone (25+5 min) | Therapeutic apheresis in autoimmune disorders: Indian perspectives (15+5 min) | Khanittha Yimsangyad (Thailand) |
| | Amber P Sanchez (USA) | Shivaram Chandrashekar (India) | KPI and CQI aspects of the therapeutic apheresis program |
| | Insights into apheresis procedures in Thailand, the national cohort (25+5 min) | Plasma exchange in TTP: mechanisms, benefits and challenges (15+5 min) | Suchada Boonkaew (Thailand) |
| | Kornchanok Vareesangthip (Thailand) | Janejira Kittivorapart (Thailand) | |
| | Green apheresis: sustainable solutions for an eco-friendly future in blood therapy (25+5 min) | Apheresis adverse events of therapeutic and donor settings in Thailand (15+5 min) | |
| | Tushar Chopra (USA) | Phandee Watanaboonyongcharoen (Thailand) | |
| | | Abstract O-012 | |
| | | The effectiveness of granulocytapheresis product transfusion in a febrile neutropenia patient with hematological malignancy in a tertiary care center at Northen India | |
| | | Ashish Jain, Dixa Kumari, Gita Negi, Uttam Kumar Nath, Daljit Kaur, Bibhant Sing, Arjun | |
| | | Kachhwaha | |
| | | Abstract O-003 | |
| | | Handling transfusion medicine staffing shortages during COVID-19 pandemic: a single- | |
| | | center perspective | |
| | | RishiRaj Sinha | |
| 10:00 - 10:30 | | Coffee Break and Poster Visiting | 1 |
| 10:30 - 12:00 | Apheresis around the world 5: | Therapeutic apheresis in neurology | Sharing experience for Apheresis in Thailand |
| | joint workshop with ASFA | | |
| | "Evidence based guidelines for the use of therapeutic apheresis medicine in solid organ | | |
| | transplantation, precision therapies for cancer, general nephrology and beyond." | | |
| | | | |
| | Chair: Chisa Yamada (USA) | Chair: Hidenori Matsuo (Japan) | Chair: Nipa Aiyasanon (Thailand) |
| | Chair: Amber P Sanchez (USA) | Chair: Saharat Aungsumart (Thailand) | Apheresis in critical care |
| | Evidence and decision making in apheresis medicine; the "ASFA Guidelines" 1986 to | Therapeutic Apheresis in Neurology: Historical Breakthroughs, Current Evidence, and | Wanna Nulert (Thailand) |
| | 2026 and beyond (25+5 min) | Future Frontiers (17+5 min) | |

| | Lours Connolly Smith (USA) | Cohorat Aungeument (Theiland) | Course homodialusis with DEDD |
|--------------|--|---|--|
| | Laura Connelly-Smith (USA) | Saharat Aungsumart (Thailand) | Couple hemodialysis with DFPP |
| | Apheresis medicine; first step in precision immunotherapy for cancer; the "designer | Evidence base of TPE in seronegative immune mediated disease. Do we need antibody | Wilaiporn Akkabut (Thailand) |
| | medicines" (Chimeric Antigen Receptor T Cells) (25+5 min) | for guiding of TPE? (17+5 min) | |
| | Nicole A. Aqui (USA) | Metha Apiwattanakul (Thailand) | Apheresis in neurology and hematology disea |
| | Immune modulation with extracorporeal phototherapy; clinical successes (25+5 min) | Apheresis therapy in the treatment strategy of autoimmune encephalitis (AE) (17+5 min) | Pattama Wimanchan (Thailand) |
| | Jennifer Schneiderman (USA) | Satoru Oji (Japan) | |
| | | Mechanism of Action of Blood Purification Discovered in Multiple Sclerosis (MS) | |
| | | Research (17+5 min) | |
| | | Youwei Lin (Japan) | |
| 2:00 - 13:00 | Lunch Symposium | Lunch Symposium | |
| | AsahiKASEI: Apheresis for tomorrow: advancing global collaboration from Japan and | Kaneka | |
| | Thailand | | |
| | Chair: Ken Yamaji (Japan) | Chair: Wolfgang Ramlow (Germany) | |
| | Speaker: Makio Kusaoi (Japan) | A novel apheresis therapy for CLTI – Rheocarna™ | |
| | | Speakers: Hitoshi Suzuki (Japan) | |
| | Speaker: Adisorn Lumpaopong (Thailand) | Usefulness of Rheocarna™ as a novel adjunctive therapy for CLTI revascularization | |
| | | Canadiana Kaisuka Miuska (Japan) | |
| | | Speakers: Keisuke Miyake (Japan) | |
| 3:00 - 14:30 | Apheresis around the world 6: | Lipoprotein(a) [Lp(a)] in cardiovascular disease, bridging the gap between | Apheresis onboarding: nursing and advanced |
| 5.00 - 14.30 | i i i i i i i i i i i i i i i i i i i | | |
| | joint workshop with SEATPEC | pathophysiology, emerging science, and clinical practice | practice providers |
| | Chair: Shanthi Viswanathan (Malaysia) | Chair: Patrick Moriarty (USA) | Chair: Narunat Keereewan (Thailand) |
| | Chair: Sasitorn Siritho (Thailand) | Chair: Adis Tasanarong (Thailand) | Utilization management for theuraputic aphere in Thailand |
| | Semi-critical use of TPE within the SEATPEC region and its challenges : case based | Lipoprotein-apheresis improves HDL proteomics and reduces the risk of aortic valve | Adisorn Lumpaopong (Thailand) |
| | (25+5 min) | stenosis in patients with elevated Lp(a) levels (25+5 min) | |
| | Jiraporn Jitprapaikulsan (Thailand) | Patrick Moriarty (USA) | |
| | TPE selection and outcome measurements within SEA: practice variabilities (25+5 min) | Lipoprotein(a) – unraveling its multifaceted role in cardiovascular pathophysiology (25+5 min) | |
| | Hiew Fu Liong (Malaysia) | Jeffrey Kroon (Netherlands) | |
| | Feasibility and effectiveness of small volume plasma exchange (SVPE): the Myanmar | Lipoprotein(a) – when science meets clinical routine (25+5 min) | |
| | experience' by adding effectiveness (25+5 min) | | |
| | Ohnmar Ohnmar (Myanmar) | Jens Ringel, Ulrike Wolf, Elke Wecke-Harbarth, Grit Waitz, Frank Breuel, Thomas | |
| | | Zimmermann, <u>Wolfgang Ramlow</u> (Germany) | |
| 4:30 - 15:00 | | Coffee Break and Poster Visiting | |
| 5:00 - 16:30 | Innovative and comparative aspects of apheresis | Vascular access strategies for apheresis medicine | Advanced technology in therapeutic apheres |
| | Chair: Shamanna S. Iyengar (India) | Chair: Laura Connelly-Smith (USA) | Chair: Narunat Keereewan (Thailand) |
| | Chair: Wanjak Pongsittisak (Thailand) | Chair: Thananda Trakarnvanich (Thailand) | Cell collection for therapeutic apheresis |
| | Veterinary use of sorbent technology for clinical apheresis (25+5 min) | Pediatric vascular access (25+5 min) | Thanatphak Warinpong (Thailand) |
| | Larry D. Cowgill (USA) | Hyogo Nakakura (Japan) | Membrane filtration: DFPP |
| | Randomized placebo (sham pheresis) controlled trial evaluating therapeutic plasma | Special aspects of vascular access for apheresis in Thailand (25+5 min) | Tipkeson Nawapanom (Thailand) |
| | exchange for the mitigation of the effects of aging in humans (25+5 min) | | |
| | Dobri Kiprov (USA) | Sukit Raksasuk (Thailand) | New innovative plasmapheresis technique fo |
| | | | critically ill pediatric - adult and kidney |
| 1 | | | |
| | | | transplantation patients |

| | Jan Kielstein (Germany) | Optimal peripheral vessels for therapeutic apheresis: machine learning-based analysis | |
|---------------|--|---|--|
| | | of ultrasound images to identify the best vascular access 10+5 | |
| | | | |
| | Abstract O-005 | Makio Kusaoi, Akie Katsuki, Hiroshi Hashimoto, Haque Hasnine, Yu Yamaji, Takumi | |
| | | Saito, Yukitomo Hagiwara, Goh Murayama, Ken Yamaji | |
| | Treatment effect of continuous plasma exchange with dialysis in organ Injury and | | |
| | significance of cell-free DNA measurement | | |
| | Yuya Suzuki, Hajime Nakae | | |
| Time | Room 1 | Room 2 | |
| | Saturday, July 1 | 9 | |
| 07:30 - 08:30 | Morning Symposium | Morning Symposium | |
| | Innovative therapies in fluid and electrolyte disorders: rhabdomyolysis and ascites | Nursing care | |
| | management | ŭ | |
| | Chair: Rasheed Abiodun Balogun (USA) | Chair: Nicole A. Aqui (USA) | |
| | Chair: Kornchanok Vareesangthip (Thailand) | Chair: Phandee Watanaboonyongcharoen (Thailand) | |
| | Hemoadsorption for myoglobin removal in rhabdomyolysis: When and how to do it | Man-machine connection; vascular access options for apheresis medicine (25+5 min) | |
| | (25+5 min) | | |
| | Jan Kielstein | Betty Doggett (USA) | |
| | Cell-free and concentrated ascites reinfusion therapy (CART) for refractory ascites | The nurse's role in therapeutic apheresis (25+5 min) | |
| | (25+5 min) | | |
| | Yuji Kamijo (Japan) | Nuntana Spilles (Thailand) | |
| 08:30 - 10:00 | Role of apheresis in nephrotic syndrome and preeclampsia | Oral abstract presentation (10+5 min) | |
| | Chair: Takafumi Ito (Japan) | Chair: Mariko Seishima (Japan) | |
| | Chair: Suchai Sritippayawan (Thailand) | Chair: Hiew Fu Liong (Malaysia) | |
| | Japanese indication and clinical efficacy of low-density lipoprotein apheresis for | | |
| | refractory nephrotic syndrome (17+5 min) | Abstract O-021 | |
| | | How is plasmapheresis positioned in the era of molecular-targeted drugs for | |
| | Eri Muso (Japan) | generalized myasthenia gravis? | |
| | | <u> </u> | |
| | Possible mechanisms of the beneficial effect of apheresis therapy on primary nephrotic | <u>Satoru Oji</u> , Masaomi Yamamoto, Tomohisa Dembo, Ken-ichi Kaida | |
| | syndrome (17+5 min) | | |
| | Hitomi Miyata (Japan) | Abstract O-018 | |
| | Japanese indication and clinical efficacy of low-density lipoprotein apheresis for chronic | | |
| | limb-threatening ischemia (17+5 min) | neurological disorders | |
| | Hitoshi Suzuki (Japan) | Kit Mun Loke, Fu Liong Hiew | |
| | A feasibility study to evaluate safety of the KNP-1000 Apheresis System in patients with | Abstract O-019 | |
| | preeclampsia with severe features (17+5 min) | | |
| | Marc Parrish (USA) | Double filtration plasmapheresis for severe steroid-resistant optic neuritis in | |
| | | neuromyelitis optica spectrum disorder | |
| | | <u>Divya Daashni Saravanan</u> , Fu Liong Hiew | |
| | | Abstract O-004 | |
| | | Efficacy of granulocyte and monocyte adsorption apheresis in plaque- type psoriasis | |
| | | | |
| | | Mariko Seishima, Miya Hiramatsu, Naoki Kamegai, Junichiro Yamamoto | |
| | | Abstract O-009 | |
| | | Rare case of atypical hemolytic uremic syndrome following infection with | |
| | | capnocytophaga canimorsus: combined treatment with Cytosorb and therapeutic | |
| | | apheresis | |
| | | Giuseppe Leonardi, Brigida Di Renzo, Patrizia Covella, Alessandra Spinelli, Cosima | |
| | | Balestra, Teresa Farina, Marco Mangiulli, Michi Recupero, Flavia Capaccio, Palmira | |
| | | Schiavone, Massimo Calò, Luigi Vernaglione | |
| | | Abstract 0-024 | |
| L | A | | |

| | 1 | | |
|---------------|---|--|--|
| | | Ten-year experience of therapeutic plasma exchange in a resource-limited center | |
| | | Weerakit Naweera, Ratthapon Chitthai, Pattaraporn Wianghok, Paradee Sithisukh, Teerapon Maungpaisan | |
| 10:00 - 10:30 | Coffee Break an | d Poster Visiting | |
| 10:30 - 12:00 | | Cell collections – principles, techniques, and quality | |
| | Chair: Lionel Rostaing (France) | Chair: Joseph Schwartz (USA) | |
| | Chair: Adisorn Lumpaopong (Thailand) | Chair: Pimpun Kitpoka (Thailand) | |
| | Solid organ transplantation; value added apheresis, or not? The kidneys (20+5min) | HPC collections for transplantation – basic concepts & techniques (25+5 min) | |
| | Chisa Yamada (USA) | Nicole A. Aqui (USA) | |
| | Optimizing transplantation: apheresis and antibody removal techniques (15+5min) | HPC collection efficiency – what & how to improve (25+5 min) | |
| | Natavudh Townamchai (Thailand) | Laura Connelly-Smith (USA) | |
| | Complications during apheresis for kidney transplant indications (15+5min) | Quality – standards to improve cell collections (25+5 min) | |
| | Chimezie Godswill Okwuonu (Nigeria) | Joseph Schwartz (USA) | |
| | Advancements in high immunologic kidney transplantation: optimizing outcomes with | | |
| | innovative plasmapheresis and hemodialysis strategies (15+5min) | | |
| | Surasak Kantachuvesiri (Thailand) | | |
| 12:00 - 13:00 | Lunch Symposium | Lunch Symposium | |
| | Apheresis in solid organ transplantation: optimizing outcomes in lung and kidney transplants | Apheresis in nephrology | |
| | Chair: Takuya Ueno (USA) | Chair: Luigi Vernaglione (Italy) | |
| | Chair: Prajej Ruangkanchanasetr (Thailand) | Chair: Kamol Khositrangsikun (Thailand) | |
| | Solid organ transplantation; value added apheresis, or not? The lungs (25+5 min) | Selective and semi-selective apheresis: How and why? (25+5 min) | |
| | Max M. Weder (USA) | Olivier Moranne (France) | |
| | Apheresis to desensitize ABO incompatible kidney transplant candidates with extremely high isoagglutinin titers (25+5 min) | Lipoprotein apheresis in FSGS (25+5 min) | |
| | Lionel Rostaing (France) | Joshua J. Zaritsky (USA) | |
| 13.00 - 14.30 | Management of plasmapheresis in children | Apheresis in ANCA-associated vasculitis | |
| | Chair: Larry Cowgill (USA) | Chair: Wladimir Szpirt (Denmark) | |
| | Chair: Konggrapun Srisuwan (Thailand) | Chair: Thatsaphan Srithongkul (Thailand) | |
| | Management of plasmapheresis in neonates and infants (15+5 min) | Does plasma exchange have a role in ANCA-associated vasculitis? (25+5 min) | |
| | | Yes, under some circumstances. | |
| | Mariko Sawada (Japan) | Wladimir M Szpirt, Balazs Odler, Andreas Kronbichler | |
| | Plasmapheresis in pediatric vasculitis and autoimmune diseases (15+5 min) | The effect of plasma exchange on early renal response among patients with ANCA- associated glomerulonephritis (25+5 min) | |
| | Sirirat Charuvanij (Thailand) | Balazs Odler, Regina Riedl, Duvuru Geetha, Wladimir M. Szpirt, Carmel Hawley, Lisa | |
| | | Uchida, Zachary S. Wallace, Giles Walters, Eri Muso, Vladimir Tesar, Charles D. Pu-sey, | |
| | | Mark A. Little, Peter A. Merkel, Michael Walsh, David R.W. Jayne, Andreas Kronbichler, | |
| | | for the PEXIVAS investigators | |
| | Plasmapheresis in children: an overview of technical aspects and experience in pediatric kidney disease (15+5 min) | The impact of kidney relapse on long-term kidney function in ANCA-associated vasculitis (25+5 min) | |
| | Konggrapun Srisuwan (Thailand) | Lisa Uchida, Vanja Ivkovic, Anna Matyjek, Duvuru Geetha, Balazs Odler, Carmel Haw- | |
| | | ley, Zachary S. Wallace, Carol McAlear, Mats Junek, Peter A. Merkel, Michael Walsh, David R.W. Jayne, Andreas Kronbichler, on behalf of the PEXIVAS investigators | |
| | Abstract O-010 | | |
| | | | |

| | Clinical Experience of Therapeutic Apheresis in Pediatrics at Phramongkutklao Hospital | | |
|---------------|--|--|--|
| | Phalita Sirichotikul, Konggrapun Srisuwan | | |
| | Abstract O-007 | | |
| | Tandem Apheresis with Continuous Renal Replacement Therapy in Pediatric Acute | | |
| | Liver Failure: A Novel Multimodal Extracorporeal Support Approach | | |
| | | | |
| | <u>Anshika Yadav</u> | | |
| 14:30 - 15:00 | Coffee Break and Poster Visiting | | |
| 15:00 - 16:00 | Closing ceremony and Awards | | |
| | Joseph Schwartz (WAA president) future of apheresis WAA perspective | | |
| | Ken Yamaji (ISFA outgoing president) | | |
| | Rasheed Balogun (ISFA incoming president) future of apheresis ISFA perspective | | |
| | Kriengsak Vareesangthip (congress president) | | |
| | | | |

*All abstract sessions has 10 minutes presentation and 5 minutes discussion